<DOC>
	<DOCNO>NCT00000656</DOCNO>
	<brief_summary>To assess safety evaluate anti-HIV effect low- , moderate- , high-dose schedule zidovudine ( AZT ) plus didanosine ( ddI ) versus ddI alone asymptomatic HIV-infected patient . Because failure long-term ( 1 year ) use , frequency toxicity , drug resistance AZT , drug combination need develop enable low , less toxic dos AZT use slow prevent development resistance , provide least effectiveness .</brief_summary>
	<brief_title>A Phase I/II , Open Label Study Evaluate Antiviral Potential Combination Zidovudine 2 ' 3'-Dideoxyinosine ( Didanosine ) Patients With Asymptomatic HIV Disease</brief_title>
	<detailed_description>Because failure long-term ( 1 year ) use , frequency toxicity , drug resistance AZT , drug combination need develop enable low , less toxic dos AZT use slow prevent development resistance , provide least effectiveness . Enrollment first 8 week study restrict hemophiliacs sexual partner hemophiliacs asymptomatic HIV disease . After initial 8 week restriction lift . Patients randomize one four treatment arm dose AZT plus ddI ddI alone .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine . Acute intermittent therapy mycostatin mycelex . Isoniazid , alternative therapy available . Allowed 2 week : Acyclovir Herpes infection ( withhold didanosine therapy ) . Acute therapy fluconazole ketoconazole . Allowed preferably continuous basis &gt; 72 hour : Acetaminophen . Ibuprofen . Nonsteroidal antiinflammatory agent . Patients must : HIV antibody positive . Asymptomatic persistent generalize lymphadenopathy . Diagnosed one list coagulopathies . OR Sexual partner someone criterion . Allowed : Basal cell carcinoma situ carcinoma cervix . NOTE : As January , 1991 full accrual patient prior AZT use reach NOW ACCRUING ONLY THOSE WITH NO PRIOR AZT USE . Hemophilia restriction lift . Prior Medication : Allowed : Zidovudine ( AZT ) total = &lt; 13 month . NOTE : As January , 1991 accrual patient reach , NOW ONLY PATIENTS WITH NO PRIOR AZT . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Unexplained temperature &gt; 38 degree C 5 consecutive day 10 day 30day period 2 year prior study entry . Unexplained diarrhea define least 3 liquid stools/day persist 7 day within 2 year prior study entry . Unintentional weight loss &gt; 10 pound &gt; 10 percent usual body weight within 2 year prior study entry . Oral hairy leukoplakia time prior study entry . Recurrent oral candidiasis unrelated use antibiotic within 2 year prior entry unrelated use antibiotic within past 3 month . Herpes zoster within 2 year prior study entry . Seizures within past 6 month currently require anticonvulsant control . Current heart disease . Current psychological emotional problem sufficient investigator 's opinion prevent adequate compliance study therapy . Gout . Concurrent Medication : Excluded : Rifampin . Chemoprophylaxis Pneumocystis carinii pneumonia aerosolize pentamidine . Intravenous pentamidine . Other antiretroviral agent , experimental medication , biological response modifier , systemic corticosteroid , cimetidine , ranitidine . Barbiturates . Oral acidify agent . Patients history follow exclude : AIDSdefining opportunistic infection , advance AIDSrelated complex , malignancy . Acute chronic pancreatitis . Grade 2 high neuropathy base Neuropathy Targeted Symptom Questionnaire . Seizures . Zidovudine therapy = &gt; 13 month . Heart disease . Psychological emotional problem sufficient investigator 's opinion prevent adequate compliance study therapy . Gout . Prior Medication : Excluded within 4 week study entry : Antiretroviral agent , include ribavirin , HPA23 , rifampin , AL721 . Excluded within 3 month study entry : Significant course immunomodulating agent , steroid ( &gt; 1 week ) , isoprinosine , thymic factor , experimental drug . Excluded within 30 day prior study entry : Neurotoxic drug . Excluded : Didanosine ( ddI ) . Dideoxycytidine ( ddC ) . Zidovudine ( AZT ) receive &gt; 13 month . Prior Treatment : Excluded within 3 month entry : Other experimental therapy . History recent alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
</DOC>